Sterling banner image2

About Us

Sterling Pharma Solutions is a global contract development and manufacturing organisation (CDMO), with 50 years’ experience in small molecule API development and manufacturing services. In December 2020 Sterling made a significant investment in ADC Bio, a UK based biotechnology company specialising in antibody drug conjugates and bioconjugation, and is working towards completing a full acquisition by the end of Q1 2021. Together, as Sterling Pharma Solution, the teams will develop an integrated service offering for existing and potential customers, which combines ADC Bio’s expertise with Sterling’s high potency small molecule expertise.

External Links

Passport Stamp for ADC EU 2022

Passport (4)

Team Members

Colin-McKee

Colin McKee

Head of Technical Services, ADC Bio

Sara-Jenkins

Sara Jenkins

ADC Commercial Manager

John-Vu

John Vu

Business Development Director

David-Molyneux

David Molyneux

Business Development Director